Meet the Program Members
The Cancer Cell Biology program, co-led by Jin Chen, MD, PhD, and Katrin Karbstein, PhD, is an active group of more than 40 basic, translational, and clinical scientists whose goal is to understand how signaling networks control cell proliferation and function, to identify drug leads, and to develop new cancer therapeutics.
Andreana Holowatyj, Ph.D., M.Sc
- Assistant Professor of Medicine
- Assistant Professor of Cancer Biology
Phone
2525 West End Avenue
Suite 334-G
Nashville, TN 37232
Suite 334-G
Nashville, TN 37232
Andreana Holowatyj, Ph.D., M.Sc
- Assistant Professor of Medicine
- Assistant Professor of Cancer Biology
615-322-0105
andreana.holowatyj@vumc.org
2525 West End Avenue
Suite 334-G
Nashville, TN 37232
Suite 334-G
Nashville, TN 37232
Research Program
Research Description
Brianna Smith, M.D., M.S.
- Assistant Professor of Pediatrics, Hematology/Oncology
Brianna Smith, M.D., M.S.
- Assistant Professor of Pediatrics, Hematology/Oncology
brianna.n.smith@vumc.org
Research Program
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager (BiTE) that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Kaitlyn Ledwitch, PhD
- Research Assistant Professor of Chemistry
Kaitlyn Ledwitch, PhD
- Research Assistant Professor of Chemistry
k.ledwitch@vanderbilt.edu
Research Program
Rachel Bonami, PhD
- Assistant Professor of Medicine
- Assistant Professor of Pathology, Microbiology and Immunology
Rachel Bonami, PhD
- Assistant Professor of Medicine
- Assistant Professor of Pathology, Microbiology and Immunology
615-875-1517
rachel.h.bonami@vumc.org
Research Program
Craig Duvall, Ph.D.
- Professor of Biomedical Engineering
- Cornelius Vanderbilt Professor, Vanderbilt University Biomedical Engineering
- Professor of Ophthalmology and Visual Sciences
Craig Duvall, Ph.D.
- Professor of Biomedical Engineering
- Cornelius Vanderbilt Professor, Vanderbilt University Biomedical Engineering
- Professor of Ophthalmology and Visual Sciences
615-322-3598
craig.duvall@Vanderbilt.Edu
Research Program
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Quincy Quick, PhD
- Associate Professor of Biological Sciences
- Tennessee State University
Quincy Quick, PhD
- Associate Professor of Biological Sciences
- Tennessee State University
615-322-2555
quincy.quick@vumc.org
Research Program
Ruben Barricarte, PhD
- Assistant Professor of Medicine
- Assistant Professor of Pathology, Microbiology and Immunology
Ruben Barricarte, PhD
- Assistant Professor of Medicine
- Assistant Professor of Pathology, Microbiology and Immunology
615-322-5762
ruben.m.barricarte@vumc.org
